Category: 97859-49-9

On May 28, 2001, Madar, D. J.; Kopecka, H.; Pireh, D.; Pease, J.; Pliushchev, M.; Sciotti, R. J.; Wiedeman, P. E.; Djuric, S. W. published an article.HPLC of Formula: 97859-49-9 The title of the article was Synthesis of N-arylated oxazolidinones via a palladium catalyzed cross coupling reaction. Application to the synthesis of the antibacterial agent Dup-721. And the article contained the following:

A method for the intermol. coupling of aryl bromides and oxazolidinones is described. Application to intermediates useful for the preparation of a known class of antibacterial agent and the synthesis of the known antibacterial oxazolidinone Dup-721 are described. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).HPLC of Formula: 97859-49-9

The Article related to arylated oxazolidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.HPLC of Formula: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On October 4, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Application of 97859-49-9 The title of the patent was Oxazolidinone compounds as antibiotics and process of preparation. And the patent contained the following:

The disclosure relates to compounds of formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The disclosure also relates to the synthesis and characterization of aforementioned substances. Compounds of formula I wherein A is absent and CH2; B is CH2 and CH2CH2; X1 is N and CR4; X2 is N and CR5; Y1 and Y2 are independently N and CR7; Z1 is O, S, NH and CH2; R1 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-6 cycloalkyl, etc.; R2 is H, halo, OH, CN, C1-6 alkoxy, etc.; R3 is H, F, C1-4 alkoxy, etc.; R4 is H, C1-4 alkoxy, C1-6 haloalkyl, etc.; R5 is H, CN, (un)substituted C1-6 alkyl, CO2H, etc.; R6 is H, C1-6 alkyl and C1-6 alkoxy; R7 is H, halo, CN, C1-6 alkoxy, etc.; and stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are claimed. Example compound II was prepared by reductive alkylation of 6-(5-(2-aminoethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with 2-(4-methyl-3,6-dioxo-4,6-dihydropyrido[2,3-b]pyrazin-5(3H)-yl)acetaldehyde. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited MIC values in the range of 0.06μg/mL to 0.5μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Application of 97859-49-9

The Article related to oxazolidinone preparation antibiotic, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Application of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On October 3, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.Electric Literature of 97859-49-9 The title of the patent was Oxazolidinone compounds as antibiotics and process of preparation. And the patent contained the following:

The disclosure relates to compounds of formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The disclosure also relates to the synthesis and characterization of aforementioned substances. Compounds of formula I wherein A is absent and CH2; B is CH2 and CH2CH2; X1 is N and CR4; X2 is N and CR5; Y1 and Y2 are independently N and CR7; Z1 is O, S, NH and CH2; R1 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C3-6 cycloalkyl, etc.; R2 is H, halo, OH, CN, C1-6 alkoxy, etc.; R3 is H, F, C1-4 alkoxy, etc.; R4 is H, C1-4 alkoxy, C1-6 haloalkyl, etc.; R5 is H, CN, (un)substituted C1-6 alkyl, CO2H, etc.; R6 is H, C1-6 alkyl and C1-6 alkoxy; R7 is H, halo, CN, C1-6 alkoxy, etc.; and stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are claimed. Example compound II was prepared by reductive alkylation of 6-(5-(2-aminoethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with 2-(4-methyl-3,6-dioxo-4,6-dihydropyrido[2,3-b]pyrazin-5(3H)-yl)acetaldehyde. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited MIC values in the range of 0.06μg/mL to 0.5μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Electric Literature of 97859-49-9

The Article related to oxazolidinone preparation antibiotic, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Electric Literature of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 29, 2001, Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Ni, Zhi-jie; Gordon, Eric published a patent.Formula: C4H7NO3 The title of the patent was Preparation of oxazolidinones as bactericides. And the patent contained the following:

Title compounds [e.g., I; R = H; R1 = SR11, CONR7R8, etc.; R7,R8,R11 = H, alkyl, (hetero)aryl, etc.] were prepared Thus, 3,4-F(Me3CO2C)C6H3NHCO2CH2Ph (preparation given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in several steps to I (R = resin, R1 = CO2C6F5) which was amidated by morpholine to give, after resin cleavage, I (R = H, R1 = CONHR8, R8 = morpholino). Data for biol. activity of I were given. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Formula: C4H7NO3

The Article related to oxazolidinone preparation bactericide, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On March 24, 2005, Hagen, Susan Elizabeth; Josyula, Vara Prasad Venkata Nagendra published a patent.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of substituted quinolones and derivatives thereof as antibacterial agents. And the patent contained the following:

Title compounds I [Z2 = aminocarbonyl, carbonylamino, CN; either D = N, E = C, F = CH or D = CH, E = N, F = CH2 if — is absent; J, K, Q = (un)substituted alkyl, N with provisions; n = 0-2; at least one of W, X, Y = NP; P = substituted quinolone] are prepared For instance, II is prepared from 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid boron difluoride chelate and N-[2-oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide to give an intermediate borate ester which is converted to the final product upon treatment with Et3N, water at reflux for 18 h. II has MIC 1 μg/mL against E. Faecalis and 0.06 μg/mL against S. aureus. I are useful for the treatment of bacterial infections. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to antibacterial agent quinolone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 31, 1995, Danielmeier, Karsten; Steckhan, Eberhard published an article.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was Efficient pathways to (R)- and (S)-5-hydroxymethyl-2-oxazolidinone and some derivatives. And the article contained the following:

Two new syntheses of enantiomerically pure (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been developed starting with D-mannitol, L-ascorbic acid and (R)- or (S)-malic acid. (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been used to synthesize some new homochiral 2-oxazolidinone derivatives The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to oxazolidinone derivative enantiomerically pure, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 19, 2002, Sciotti, Richard J.; Pliushchev, Marina; Wiedeman, Paul E.; Balli, Darlene; Flamm, Robert; Nilius, Angela M.; Marsh, Kennan; Stolarik, DeAnne; Jolly, Robert; Ulrich, Roger; Djuric, Stevan W. published an article.Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. And the article contained the following:

A novel series of antimicrobials of the oxazolidinone class is disclosed. These compounds are characterized relative to previously described analogs by a ‘halostilbene-derived’ pharmacophore and demonstrate enhanced antimicrobial activity against key Gram-pos. pathogens when compared to Linezolid. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to antimicrobial oxazolidinone compound preparation biol evaluation, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On July 24, 2014, Basarab, Gregory Steven; Gowravaram, Madhusudhan Reddy; Hauck, Sheila Irene; Zhou, Fei published a patent.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of spiro[oxazino[4,3-a]isoxazolo[4,5-g]quinoline-pyrimidine]trione compounds and methods for treating bacterial infections. And the patent contained the following:

Compounds of formula I, pharmaceutically acceptable salts thereof, and uses of the compounds of formula I for treating bacterial infections are disclosed. Compounds of formula I wherein X is F and Cl; R1 is H, (un)substituted Ph, CN, tetrahydropyranyl, etc.; R2 is H, CN, pyridinyl and (un)substituted C1-3 alkyl; R3 is H and C1-3 alkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by spirocyclization of (2R)-1-[[5-(1,3-Dioxolan-2-yl)-6,7-difluoro-1,2-benzoxazol-3-yl]amino]propan-2-ol with barbituric acid. The invention compounds were evaluated for their DNA gyrase inhibitory activity (data given). The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to spirooxazinoisoxazoloquinoline pyrimidinetrione preparation treatment bacterial infection, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 22, 2002, Wiedeman, Paul E.; Djuric, Steven W.; Pilushchev, Marina; Sciotti, Richard J.; Madar, David J.; Kopecka, Hana published a patent.Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of oxazolidinones as antibacterial agents. And the patent contained the following:

Title compounds [I; A = Ph, substituted 5-membered aromatic ring containing 1-2 N, O, S, or 6-membered aryl containing 1-2 N atoms; R1, R2 = H, alkyl, alkoxy, thioalkoxy, cycloalkyl, OH, amino, aminoalkyl, halo, haloalkyl, perfluoroalkyl; R3, R4, R5 = H, carboxamido, cyano, halo, NO2, perfluoroalkyl, (substituted) alkyl, alkanoyl, cycloalkyl, cyclothioalkoxy, cycloalkylsulfinyl, cycloalkoxycarbonyl, thioalkoxy, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, cycloalkenyl, thiocycloalkenyloxy, cycloalkenylsulfinyl, cycloalkenylsulfonyl, aryl, aralkyl, arylthio, arylsulfinyl, arylsulfonyl, aryloxycarbonyl, heteroaryl, heteroarylalkyl, etc.; R6 = NHR7, N-phthalimido, NR7R8, NR8CO2R9, NR8CON(R8)2, OR9, SR9, SOR9, SO2R9; R7 = (substituted) alkanoyl, aryloyl, thioalkanoyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclylalkyl, etc.; R8 = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclylalkyl, protecting group; R9 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heteroarylalkyl, heterocycle, etc.] were prepared as antibacterial agents. N-[[(5S)-3-[4-(2,2-dibromovinyl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide, 5-acetyl-2-thienylboronic acid, tris(dibenzylideneacetone)dipalladium, and aqueous Na2CO3 in deoxygenated dimethoxyethane were heated at 55° for 20 h to give N-[[(5S)-3-[4-[(Z)-2-(5-acetyl-2-thienyl)-2-bromoethenyl]-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide. In an antibacterial activity assay, I inhibited the growth of Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Enterococcus faecium, and Streptococcus pneumoniae with MIC’s in the range of about 0.125 μg/mL to about 128 μg/mL. I are also useful for treating psoriasis, arthritis, and toxicity due to chemotherapy (no data). The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to oxazolidinone preparation bacterial infection psoriasis arthritis chemotherapy toxicity treatment, thienyl oxazolidinylmethyl acetamide preparation antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On April 18, 2006, Kamal, Ahmed; Khanna, G. B. Ramesh; Krishnaji, T.; Ramu, R. published an article.Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was Lipase-mediated resolution of 3-hydroxy-4-trityloxybutanenitrile: synthesis of 2-amino alcohols, oxazolidinones and GABOB. And the article contained the following:

Lipase-mediated kinetic resolution of 3-hydroxy-4-trityloxybutanenitrile gave the (S)-alc. and (R)-acetate in good yields and high enantioselectivities. The resolution using Pseudomonas cepacia lipase (Burkholderia cepacia) immobilized on modified ceramic particles (PS-C) in diisopropyl ether gave the best results. The use of base additives in this transesterification drastically reduces the reaction time without effecting the yields or enantioselectivities. Resolved 3-hydroxy-4-trityloxybutanenitrile has been utilized for the synthesis of enantiomerically pure 5-tosyloxymethyl-1,3-oxazolidine-2-one, which is an important intermediate for the preparation of β-adrenergic blocking agents and oxazolidinone based antimicrobial agents. Enantiomerically pure (R)-3-hydroxy-4-trityloxybutanenitrile and (S)-5-tosyloxymethyl-1,3-oxazolidine-2-one have been utilized in the enantioconvergent synthesis of (R)-GABOB. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to lipase kinetic resolution hydroxytrityloxybutanenitrile, Fermentation and Bioindustrial Chemistry: Pharmaceuticals (Including Nutrients) and other aspects.Name: (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem